A point that illustrates this quite nicely-one that’s often shared in the longevity circles-is: “Preventing decline is the new cure.” Bill Gates has now put that idea front and center by arguing that blood tests for Alzheimer’s biomarkers should become part of routine medical care once adults hit 60. He bases his argument not only on the personal experience of his father, who lived with Alzheimer’s until he died at 94, but also on a forward-looking belief that earlier detection can reshape what healthy aging looks like.
Gates supports groups developing the blood-based diagnostics, which detect amyloid proteins long before symptoms surface. “For the broad population, probably once you turn 60 or so, that should be part of the routine blood test,” he told CBS Sunday Morning. He added that the test is inexpensive and could inform access to emerging “clearing drugs” designed to prevent Alzheimer’s from taking hold. The treatments he mentioned are part of a wider scientific shift: monoclonal antibodies such as lecanemab and donanemab, which clinical trials show can slow declines in early Alzheimer’s by helping the body clear beta-amyloid. These treatments, delivered via infusions every two to four weeks, also come with known risks, including infusion reactions and, in rare cases, brain swelling or bleeding. But the fact they exist signals that the field has entered a new era in which prevention, not late-stage management, is increasingly possible.
But the prospect of widely available biomarker testing goes beyond the initiatives Gates has pursued. In May 2025, the FDA approved the first blood test aimed at helping to diagnose Alzheimer’s by measuring tau proteins indicative of amyloid plaques, with over 90% accuracy-Lumipulse. The advantage of the test is that it reduces reliance on either invasive lumbar punctures or expensive imaging; rather, it offers an initial assessment tool for adults over 50 with early memory concerns via a simple blood draw with results within days. Meanwhile, the Elecsys pTau181 test was recently cleared by the FDA as the first primary-care blood tool designed specifically to rule out amyloid pathology, which helps clinicians determine which of their patients would not require further testing with a focus on Alzheimer’s. These tools reflect a broader trend toward earlier, less-invasive cognitive assessment supported by innovations highlighted in NIH dementia research.
This transformation comes at a critical juncture. With the number of aging populations growing globally, societies face increasing burdens of chronic disease and also mounting pressure on healthcare systems. Studies summarized in national analyses of demographic trends indicate that by 2030, one in five U.S. residents will be retirement age, while the population over 85-those most vulnerable to dementia-will triple by 2050. Chronic conditions already drive overwhelming demand: older adults with multiple chronic illnesses account for over 90% of Medicare spending. Breakthroughs in early detection, such as the p‑tau217 assays highlighted in recent NIH-supported research, have shown that blood biomarkers can outperform imaging for accuracy and help identify disease in its silent phase-precisely when prevention has the greatest potential.
He frames prevention as both a personal and societal opportunity. He points to a future in which healthier brains translate into longer, more productive lives. As he put it: What about a society where we can prevent almost all of Alzheimer’s, and your 70s, 80s, even if you’re lucky your 90s, you’re fully capable as grandparent or if you want to continue working. His optimism intersects with global longevity research showing that reducing noncommunicable diseases yields economic and wellbeing gains across generations. Reports on healthy ageing emphasize that when people stay cognitively strong, workforce participation increases, caregiving burdens ease, and families face fewer disruptive health shocks.
From research labs and public health organizations to primary care offices, a new model of ageing is taking shape-one in which early detection becomes routine, preventive treatments become increasingly precise, and the prospect of entering one’s ninth decade with clarity and capability becomes more realistic. For the health-conscious adult and caregivers who monitor such advances, the landscape is shifting toward empowerment through knowledge: simple blood tests could soon illuminate brain health years before symptoms appear, opening doors to interventions that preserve independence, purpose, and longevity.
